Workflow
其他生物制品
icon
Search documents
康弘药业跌2.02%,成交额1.06亿元,主力资金净流出117.29万元
Xin Lang Cai Jing· 2025-10-10 06:31
10月10日,康弘药业盘中下跌2.02%,截至14:13,报35.92元/股,成交1.06亿元,换手率0.42%,总市值 330.94亿元。 资金流向方面,主力资金净流出117.29万元,特大单买入260.92万元,占比2.47%,卖出201.25万元,占 比1.90%;大单买入1200.69万元,占比11.36%,卖出1377.64万元,占比13.03%。 康弘药业今年以来股价涨89.05%,近5个交易日跌2.79%,近20日跌8.72%,近60日涨23.48%。 截至9月30日,康弘药业股东户数2.40万,较上期减少3.67%;人均流通股28624股,较上期增加3.81%。 2025年1月-6月,康弘药业实现营业收入24.54亿元,同比增长6.95%;归母净利润7.30亿元,同比增长 5.41%。 分红方面,康弘药业A股上市后累计派现20.38亿元。近三年,累计派现10.40亿元。 机构持仓方面,截止2025年6月30日,康弘药业十大流通股东中,香港中央结算有限公司位居第四大流 通股东,持股2727.50万股,相比上期减少531.59万股。大成睿享混合A(008269)位居第六大流通股 东,持股1225. ...
甘李药业跌2.01%,成交额6.90亿元,主力资金净流出3870.82万元
Xin Lang Zheng Quan· 2025-10-10 05:09
10月10日,甘李药业盘中下跌2.01%,截至13:04,报74.13元/股,成交6.90亿元,换手率1.65%,总市值 442.78亿元。 甘李药业所属申万行业为:医药生物-生物制品-其他生物制品。所属概念板块包括:高派息、基金重 仓、融资融券、中盘、创新药等。 截至6月30日,甘李药业股东户数7.73万,较上期增加3.08%;人均流通股7165股,较上期减少2.99%。 2025年1月-6月,甘李药业实现营业收入20.67亿元,同比增长57.18%;归母净利润6.04亿元,同比增长 101.96%。 分红方面,甘李药业A股上市后累计派现16.12亿元。近三年,累计派现10.18亿元。 机构持仓方面,截止2025年6月30日,甘李药业十大流通股东中,香港中央结算有限公司位居第三大流 通股东,持股750.99万股,相比上期增加17.48万股。招商国证生物医药指数A(161726)位居第五大流 通股东,持股580.26万股,相比上期减少24.16万股。南方中证500ETF(510500)位居第六大流通股 东,持股536.87万股,相比上期增加69.27万股。创新药(159992)位居第八大流通股东,持股340. ...
君实生物跌2.03%,成交额1.93亿元,主力资金净流出3038.12万元
Xin Lang Cai Jing· 2025-10-09 02:09
资料显示,上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室,成立日期2012年12月27日,上市日期2020年7月15日,公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为:药品销售90.67%,技术许可及特许权使用收入8.74%,技术服务及其他 0.59%。 来源:新浪证券-红岸工作室 10月9日,君实生物盘中下跌2.03%,截至10:03,报40.62元/股,成交1.93亿元,换手率0.61%,总市值 417.04亿元。 资金流向方面,主力资金净流出3038.12万元,特大单买入1470.52万元,占比7.62%,卖出3328.90万 元,占比17.25%;大单买入5172.48万元,占比26.81%,卖出6352.22万元,占比32.92%。 君实生物今年以来股价涨48.63%,近5个交易日跌2.52%,近20日跌12.40%,近60日涨7.09%。 君实生物所属申万行业为:医药生物-生物制品-其他生物制品。所属概念板块包括:生物医药、创新 药 ...
康弘药业涨2.00%,成交额1.63亿元,主力资金净流出112.69万元
Xin Lang Cai Jing· 2025-09-30 06:54
Core Viewpoint - Kanghong Pharmaceutical has shown significant stock performance with a year-to-date increase of 95.79%, despite a recent decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, up 5.41% year-on-year [2]. Stock Market Activity - As of September 30, the stock price of Kanghong Pharmaceutical was 37.20 yuan per share, with a market capitalization of 34.273 billion yuan. The stock experienced a trading volume of 163 million yuan and a turnover rate of 0.65% [1]. - The stock has seen a net outflow of 1.1269 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of September 19, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, with an average of 27,573 circulating shares per person, a decrease of 0.74% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].
特宝生物涨2.01%,成交额1.65亿元,主力资金净流入227.88万元
Xin Lang Cai Jing· 2025-09-29 06:51
Core Viewpoint - The stock of TEBIO has shown a positive trend with a year-to-date increase of 15.02% and a recent rise of 5.63% over the last five trading days, indicating strong market interest and performance [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96% [2]. - The net profit attributable to shareholders for the same period was 428 million yuan, reflecting a year-on-year increase of 40.60% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 8,439, up by 13 compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with both increasing their holdings [3].
诺唯赞涨2.03%,成交额3811.18万元,主力资金净流出163.85万元
Xin Lang Zheng Quan· 2025-09-26 05:56
9月26日,诺唯赞盘中上涨2.03%,截至13:48,报23.13元/股,成交3811.18万元,换手率0.42%,总市值 92.00亿元。 资料显示,南京诺唯赞生物科技股份有限公司位于江苏省南京经济技术开发区科创路红枫科技园D2 栋,成立日期2012年3月16日,上市日期2021年11月15日,公司主营业务涉及围绕酶、抗原、抗体等功 能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业,依托于自主建立的关键共性技术 平台,先后进入了生物试剂、体外诊断业务领域,并正在进行抗体药物的研发。主营业务收入构成为:生 物试剂81.86%,诊断试剂9.99%,耗材等材料3.15%,仪器设备2.96%,技术服务1.85%,其他0.18%。 诺唯赞所属申万行业为:医药生物-生物制品-其他生物制品。所属概念板块包括:基因测序、抗原检 测、体外诊断、合成生物、小盘等。 截至6月30日,诺唯赞股东户数8596.00,较上期增加2.37%;人均流通股46269股,较上期减少2.31%。 2025年1月-6月,诺唯赞实现营业收入6.06亿元,同比减少6.63%;归母净利润312.94万元,同比减少 80.63%。 资金流向方 ...
特宝生物涨2.08%,成交额1.24亿元,主力资金净流入528.78万元
Xin Lang Cai Jing· 2025-09-25 05:27
Company Overview - Teabo Bioengineering Co., Ltd. is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1][2] - The main business revenue composition includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other (supplement) (0.27%) [1] Financial Performance - For the first half of 2025, Teabo Bio achieved operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%, and a net profit attributable to shareholders of 428 million yuan, a year-on-year increase of 40.60% [2] - Since its A-share listing, Teabo Bio has distributed a total of 577 million yuan in dividends, with 506 million yuan distributed over the past three years [2] Stock Performance - As of September 25, Teabo Bio's stock price increased by 2.08%, reaching 83.08 yuan per share, with a total market capitalization of 33.797 billion yuan [1] - Year-to-date, the stock price has risen by 14.20%, with a 4.46% increase over the last five trading days and a 14.94% increase over the last 60 days [1] Shareholder Information - As of June 30, the number of shareholders for Teabo Bio was 8,439, an increase of 13.00% from the previous period, while the average circulating shares per person decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation 50 ETF and E Fund SSE Sci-Tech Innovation 50 ETF increased their holdings [2]
君实生物涨2.18%,成交额5648.08万元,主力资金净流入31.36万元
Xin Lang Cai Jing· 2025-09-25 01:44
资料显示,上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室,成立日期2012年12月27日,上市日期2020年7月15日,公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为:药品销售90.67%,技术许可及特许权使用收入8.74%,技术服务及其他 0.59%。 君实生物所属申万行业为:医药生物-生物制品-其他生物制品。所属概念板块包括:生物医药、创新 药、抗癌药物、抗癌治癌、猴痘概念等。 来源:新浪证券-红岸工作室 9月25日,君实生物盘中上涨2.18%,截至09:35,报42.58元/股,成交5648.08万元,换手率0.17%,总市 值437.16亿元。 资金流向方面,主力资金净流入31.36万元,特大单买入306.69万元,占比5.43%,卖出0.00元,占比 0.00%;大单买入1392.73万元,占比24.66%,卖出1668.05万元,占比29.53%。 君实生物今年以来股价涨55.80%,近5个交易日跌6.89%,近20日跌3.16%, ...
君实生物涨0.22%,成交额6.21亿元,近3日主力净流入-1.47亿
Xin Lang Cai Jing· 2025-09-24 09:11
Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biopharmaceutical developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi's self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - Junshi's subsidiary, JunTuo Biotech, is developing vaccine-related products, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - The company has partnered with several institutions, including Peking University and the Chinese Academy of Sciences, to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 24, Junshi Biosciences' stock rose by 0.22%, with a trading volume of 621 million yuan and a turnover rate of 1.95%, bringing the total market capitalization to 42.782 billion yuan [1]. - The stock has seen a net outflow of 27.407 million yuan from major funds, indicating a lack of strong buying interest [4][5].
长春高新涨2.08%,成交额8.08亿元,主力资金净流入1827.18万元
Xin Lang Zheng Quan· 2025-09-24 06:37
Group 1 - The core viewpoint of the news is that Changchun High-tech has shown a significant stock performance with a year-to-date increase of 24.97%, despite a recent decline of 2.27% over the last five trading days [1] - As of September 24, the stock price reached 121.07 yuan per share, with a total market capitalization of 49.389 billion yuan [1] - The company has seen a net inflow of main funds amounting to 18.2718 million yuan, with large orders contributing significantly to the trading volume [1] Group 2 - Changchun High-tech's main business revenue composition is 92.83% from pharmaceuticals, 6.81% from real estate, and 0.36% from services [1] - As of June 30, the company reported a revenue of 6.603 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 0.54%, while the net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - The company has distributed a total of 4.791 billion yuan in dividends since its A-share listing, with 3.259 billion yuan distributed in the last three years [3] Group 3 - As of June 30, 2025, the number of shareholders decreased by 12.78% to 109,100, while the average circulating shares per person increased by 14.66% to 3,662 shares [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, holding 8.4381 million shares [3] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is associated with various investment concepts such as Northeast revitalization and high dividend stocks [2]